US20210023032A1 - Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver - Google Patents
Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver Download PDFInfo
- Publication number
- US20210023032A1 US20210023032A1 US17/064,154 US202017064154A US2021023032A1 US 20210023032 A1 US20210023032 A1 US 20210023032A1 US 202017064154 A US202017064154 A US 202017064154A US 2021023032 A1 US2021023032 A1 US 2021023032A1
- Authority
- US
- United States
- Prior art keywords
- compound
- liver
- pharmaceutically acceptable
- fibrosis
- hepatic fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 206010016654 Fibrosis Diseases 0.000 title description 23
- 230000004761 fibrosis Effects 0.000 title description 22
- 210000004185 liver Anatomy 0.000 title description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 25
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000002000 scavenging effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 230000000254 damaging effect Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 14
- KPRZOPQOBJRYSW-UHFFFAOYSA-N 2-(aminomethyl)phenol Chemical compound NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 73
- 229910052757 nitrogen Inorganic materials 0.000 description 30
- 229910052799 carbon Inorganic materials 0.000 description 29
- 229910052760 oxygen Inorganic materials 0.000 description 25
- 229910052717 sulfur Inorganic materials 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000004024 hepatic stellate cell Anatomy 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 12
- 230000004913 activation Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- -1 lipid aldehydes Chemical class 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 0 [2*]C1=C([2*])C(O)=C(C([4*])N)C([2*])=C1[3*] Chemical compound [2*]C1=C([2*])C(O)=C(C([4*])N)C([2*])=C1[3*] 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 108090000623 proteins and genes Chemical class 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000003352 fibrogenic effect Effects 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 239000002516 radical scavenger Substances 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000011903 nutritional therapy Methods 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- JAXQXVQWDDIGEH-UHFFFAOYSA-N CC1=C(O)C(CN)=CC([N+](=O)[O-])=C1.CC1=C(O)C(CN)=CC=C1.CC1=CC=C(O)C=C1CN.NCC1=CC(CO)=CC=C1O.NCC1=CC(Cl)=CC=C1O.NCC1=CC=CC=C1O Chemical compound CC1=C(O)C(CN)=CC([N+](=O)[O-])=C1.CC1=C(O)C(CN)=CC=C1.CC1=CC=C(O)C=C1CN.NCC1=CC(CO)=CC=C1O.NCC1=CC(Cl)=CC=C1O.NCC1=CC=CC=C1O JAXQXVQWDDIGEH-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- GAYQBTKLXLFDFL-UHFFFAOYSA-N C=C=C=O.CC1=CC=C(CO)C=C1C(N)CC(=O)O.CC1=CC=CC=C1C(N)OC=O.[H]C1=CC=C(C)C(C(N)OC=O)=C1 Chemical compound C=C=C=O.CC1=CC=C(CO)C=C1C(N)CC(=O)O.CC1=CC=CC=C1C(N)OC=O.[H]C1=CC=C(C)C(C(N)OC=O)=C1 GAYQBTKLXLFDFL-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000219051 Fagopyrum Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101150077804 TIMP1 gene Proteins 0.000 description 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 125000005233 alkylalcohol group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical compound NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004500 stellate cell Anatomy 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- FQEIMBRMJLRZJH-UHFFFAOYSA-N 4-(aminomethyl)-2-hexyl-5-(hydroxymethyl)pyridin-3-ol Chemical compound C(CCCC)CC1=NC=C(C(=C1O)CN)CO FQEIMBRMJLRZJH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 101150088055 BAMBI gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IWUXUEHWVIAVME-UHFFFAOYSA-N C.CC1=C(C)C(CN)=CC=C1.CC1=CC=C(C)C(CN)=C1.CC1=CC=C(CN)C(C)=C1.CC1=CC=CC=C1CN.CCC1=CC=C(C)C(CN)=C1.CCC1=CC=C(CN)C(C)=C1 Chemical compound C.CC1=C(C)C(CN)=CC=C1.CC1=CC=C(C)C(CN)=C1.CC1=CC=C(CN)C(C)=C1.CC1=CC=CC=C1CN.CCC1=CC=C(C)C(CN)=C1.CCC1=CC=C(CN)C(C)=C1 IWUXUEHWVIAVME-UHFFFAOYSA-N 0.000 description 1
- YVENQLXDNBZHRP-UHFFFAOYSA-N C.CC1=CC=CC=C1CN.CCC1=CC=C(CN)C(O)=C1 Chemical compound C.CC1=CC=CC=C1CN.CCC1=CC=C(CN)C(O)=C1 YVENQLXDNBZHRP-UHFFFAOYSA-N 0.000 description 1
- MFCVJPGPTUTVNT-UHFFFAOYSA-N C=O.CC1=C(C)C(CN)=C(C2=CC=CC=C2)C=N1.CC1=C(C)C(CN)=C(O)C=N1.CC1=C(CN)C(O)=C(C)N=C1.CCCOCCCC1=C(CN)C(C)=C(C)N=C1.CCOCCCC1=C(CN)C(C)=C(C)N=C1 Chemical compound C=O.CC1=C(C)C(CN)=C(C2=CC=CC=C2)C=N1.CC1=C(C)C(CN)=C(O)C=N1.CC1=C(CN)C(O)=C(C)N=C1.CCCOCCCC1=C(CN)C(C)=C(C)N=C1.CCOCCCC1=C(CN)C(C)=C(C)N=C1 MFCVJPGPTUTVNT-UHFFFAOYSA-N 0.000 description 1
- 101150091777 CASP1 gene Proteins 0.000 description 1
- PMIPUGUHJWYAOG-UHFFFAOYSA-N CC1=C(C)C(CN)=CC=C1.CC1=CC=C(C)C(CN)=C1.CC1=CC=C(CN)C(C)=C1.CC1=CC=CC=C1CN.CCC1=CC=C(C)C(CN)=C1.CCC1=CC=C(CN)C(C)=C1 Chemical compound CC1=C(C)C(CN)=CC=C1.CC1=CC=C(C)C(CN)=C1.CC1=CC=C(CN)C(C)=C1.CC1=CC=CC=C1CN.CCC1=CC=C(C)C(CN)=C1.CCC1=CC=C(CN)C(C)=C1 PMIPUGUHJWYAOG-UHFFFAOYSA-N 0.000 description 1
- QAXHZIPENVQZHJ-UHFFFAOYSA-N CC1=C(O)C(CN)=C(CO)C=N1.CC1=CC=C(O)C(CN)=C1.CCC1=CC=C(CN)C(O)=C1.CCCCCOCC1=C(CN)C(O)=C(C)N=C1.CCOCC1=C(CN)C(O)=C(C)N=C1.COC1=C(O)C(CN)=CC=C1.COC1=CC=C(O)C(CN)=C1.NCC1=CC=CC=C1O Chemical compound CC1=C(O)C(CN)=C(CO)C=N1.CC1=CC=C(O)C(CN)=C1.CCC1=CC=C(CN)C(O)=C1.CCCCCOCC1=C(CN)C(O)=C(C)N=C1.CCOCC1=C(CN)C(O)=C(C)N=C1.COC1=C(O)C(CN)=CC=C1.COC1=CC=C(O)C(CN)=C1.NCC1=CC=CC=C1O QAXHZIPENVQZHJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101150093076 IL18 gene Proteins 0.000 description 1
- 101150012417 IL1B gene Proteins 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100490443 Mus musculus Acvr1 gene Proteins 0.000 description 1
- 101150061038 NLRP3 gene Proteins 0.000 description 1
- 101150000806 Nlrp1a gene Proteins 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 101150078768 Pdk4 gene Proteins 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101150000629 TGFB1 gene Proteins 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000013237 diet-induced animal model Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the present invention relates to a composition
- a composition comprising a gamma-ketoaldehyde scavenging compound, such as 2-Hydroxybenzylamine (2-HOBA), and methods of administering a gamma-ketoaldehyde scavenger to treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of the liver.
- a gamma-ketoaldehyde scavenging compound such as 2-Hydroxybenzylamine (2-HOBA)
- Liver fibrosis is a histological change caused by liver inflammation and/or chronic injury. Damage to the liver causes liver stellate cells to become overactive and triggers the extra cellular matrix (ECM) synthesis to increase. Excess amounts of collagen fiber deposits occurs in the extra-cellular spaces of the liver cells which causes the liver cells to lose blood infusion and become hardened. Fibrosis is a common aspect of many liver diseases and is defined as the formation of scar tissue in the liver.
- hepatic fibrosis including but not limited to hepatitis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), toxins, alcoholic liver disease (ALD), genetic conditions, cholestatic disorders, and autoimmune diseases.
- NASH nonalcoholic steatohepatitis
- NAFLD nonalcoholic fatty liver disease
- ALD alcoholic liver disease
- Indicators of liver fibrosis included deposition of fibrotic tissue and activation of the fibrogenesis cascade. Fibrosis may produce permanent scarring of the hepatic tissue which is known as cirrhosis.
- ⁇ -ketoaldehydes are highly reactive lipid aldehydes that rapidly react with lysine residues and phosphatidylethanolamine to form adducts.
- ⁇ -KA lipid and protein adducts have been observed in several animal models of liver disease as well as in humans with NASH. Preliminary data from humans with NASH also indicate elevated ⁇ -KA-protein adduct formation in liver, and ⁇ -KA-protein adducts similarly induce liver injury.
- ⁇ -KA-protein adducts are linked to the loss of protein function, mitochondrial dysfunction, ER stress, and pro-inflammatory cytokine expression.
- 2-hydroxy-benzylamine (2-HOBA or salicylamine), a staple of buckwheat, was found to be a potent scavenger of ⁇ -KAs scavenging ⁇ -KAs 980-fold faster than the rate of formation of ⁇ -KA-protein adducts.
- 2-HOBA is 980 times more reactive than lysine with ⁇ -KAs. Importantly, they showed that this ⁇ -KA scavenger does not inhibit cyclooxygenase enzymes.
- 2-HOBA dramatically protected HepG2 cells against H 2 O 2 -induced cytotoxicity.
- HSCs human hepatic stellate cells
- HSCs which make up 10% of resident liver cells
- HSCs are quiescent in normal, healthy liver.
- HSCs become activated and transdifferentiate into proliferative, inflammatory myofibroblasts, which are characterized by enhanced extracellular matrix production.
- activated HSCs are well-established as the major fibrogenic cells in the liver and are strongly implicated in the development hepatic fibrosis in states of chronic liver injury.
- Oxidative stress particularly the products of lipid oxidation, has direct pro-inflammatory/pro-fibrogenic effects on HSCs.
- ⁇ KA novel HSC activators by exposing primary human HSC to synthetic 15-E 2 -isolevuglandin (15-E2-IsoLG). Exposure to non-cytotoxic levels of 15-E 2 -IsoLG promoted HSC activation, as evidenced by upregulated ⁇ -SMA expression, MAPK activation, and increased cytokine production.
- compositions of the present invention do not present the adverse effects or toxicity associated with existing therapeutics for treating liver diseases such as NASH.
- the isoketal scavangers of the present invention are compounds such as salicylamine (SA), for example, and analogs thereof.
- SA salicylamine
- the present invention includes use of gamma ketoaldehyde scavengers, including 2-HOBA, to scavenge toxic oxidized lipids (ketoaldehydes) to treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of the liver hepatic fibrosis.
- gamma ketoaldehyde scavengers including 2-HOBA
- Disclosed is a method for treating, preventing and/or attenuating hepatic fibrosis that comprises identifying a subject in need of treatment, prevention and/or attenuation of hepatic fibrosis, and administering to said subject an effective isoLG scavenging amount of at least on compound of the following formula:
- R 2 is independently chosen from H, substituted or unsubstituted alkyl;
- R 3 is H, halogen, alkyl, alkoxy, hydroxyl, nitro;
- R 4 is H, substituted or unsubstituted alkyl, carboxyl; and pharmaceutically acceptable salts thereof.
- R 2 is independently chosen from H, ethyl, methyl.
- the compound is 2-hydroyxbenzylamine, methyl-2-hydroyxbenzylamine, ethyl-2-hydroyxbenzylamine.
- the compound is:
- the compound is:
- the disclosed treating step inhibits the progression of hepatic fibrosis.
- the disclosed treating step attenuates the severity of hepatic fibrosis. Also, in one embodiment, the disclosed treating step mitigates the damaging effects of hepatic fibrosis.
- the compound or pharmaceutically acceptable salt thereof is administered in a composition that comprises said compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- One object of the present invention is to provide compositions used treat, prevent, attenuate, reduce, slow the progression of, and/or improve hepatic fibrosis.
- Another object of the present invention is to provide a therapeutic or effect amount of a preparation of the compound of the present invention to treat, prevent, attenuate, reduce, slow the progression of, or improve the symptoms of hepatic fibrosis and/or reduces the severity of hepatic fibrosis symptoms.
- a further object of the present invention includes providing a novel nutritional therapy that will treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of liver fibrosis.
- the nutritional therapy can be used to improve overall liver health and support healthy liver function.
- An additional object of the present invention includes providing compositions and methods of use of 2-HOBA, alternatively named salicylamine.
- SAM 2-hydroxylbenzylamine
- PPM pentylpyridoxamine
- FIGS. 1 a to 1 b are images of slides depicting Picosirius Red staining of fibrosis in control and 2-HOBA treated mice.
- FIG. 2 is a graph depicting the fibrosis score in control and 2-HOBA treated mice.
- FIG. 3 depicts gene expression profiles by qRT-PCR.
- compositions described herein are used treat, prevent, attenuate, reduce, slow the progression of, and/or improve hepatic fibrosis.
- a therapeutic or effect amount is a preparation of the compound of the present invention that treat, prevent, attenuate, reduce, slow the progression of, or improve the symptoms of hepatic fibrosis and/or reduces the severity of hepatic fibrosis symptoms.
- the present invention includes a novel nutritional therapy that will treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of liver fibrosis.
- the nutritional therapy can be used to improve overall liver health and support healthy liver function.
- the present invention comprises a means to specifically prevent the formation of ⁇ KA-adducts in the liver using a class of bifunctional electrophile (BFE) “scavenger” molecules.
- BFE bifunctional electrophile
- a series of phenolic amines that includes pyridoxamine and its water soluble derivative 2-HOBA, a natural product of buckwheat seed comprise the preferred embodiment.
- 2-HOBA in particular reacts 980-fold faster with IsoLGs than with lysine, preventing protein and lipid adduction in vitro and in vivo.
- the present invention includes compositions and methods of use of 2-HOBA, alternatively named salicylamine, SAM, 2-hydroxylbenzylamine, and pentylpyridoxamne (PPM).
- 2-HOBA alternatively named salicylamine, SAM, 2-hydroxylbenzylamine, and pentylpyridoxamne (PPM).
- Examples of compounds of the present invention include, but are not limited (o, compounds selected from the formula or analogs thereof, and pharmaceutical salts thereof:
- R is N or C
- R 2 is independently H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 2 , R 3 and R 4 , and may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 3 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 4 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 5 is a bond, H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 4 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- Another embodiment of the present invention includes compounds of the following formula, and their use in methods for treating, preventing, or ameliorating liver fibrosis to a subject with or at risk of liver fibrosis:
- R is N or C
- R 2 is independently H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 2 , R 3 and R 4 , and may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 3 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 4 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 5 is a bond, H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 4 to form an optionally substituted C 3 -8 membered ring containing C, O, S or N; and stereoisomers and analogs thereof.
- the compound may be selected from the compounds disclosed herein.
- the compound may be salicylamine.
- Other compounds that may be used include methyl-2-HOBA or ethyl-2-HOBA.
- the present invention includes administering to a patient in need thereof an effective amount of at least one isoLG scavenger compound of the present invention, or a pharmaceutically acceptable salt thereof.
- Another embodiment of the present invention is a method for treating, preventing, or ameliorating liver fibrosis to a subject with or at risk of liver fibrosis, thereby inhibiting or treating the liver fibrosis, comprising the step of co-administering to the subject at least one compound in a dosage and amount effective to treat the dysfunction in the mammal, the compound having a structure represented by a compound of the following formula:
- R is N or C
- R 2 is independently H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 2 , R 3 and R 4 , and may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 3 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 4 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
- R 5 is a bond, H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 4 to form an optionally substituted C 3-8 membered ring containing C, O, S or N; and stereoisomers and analogs thereof; with a drug having a known side effect of treating, preventing, or ameliorating liver fibrosis.
- Examples of compounds that may be used with the methods disclosed herein include, but are not limited to, compounds selected from the formula:
- R is N or C
- R 2 is independently H, substituted or unsubstituted alkyl;
- R 3 is H, halogen, alkoxy, hydroxyl, nitro;
- R 4 is H, substituted or unsubstituted alkyl, carboxyl; and pharmaceutically acceptable salts thereof.
- R 2 is independently chosen from H, substituted or unsubstituted alkyl; R 3 is H, halogen, alkyl, alkoxy, hydroxyl, nitro; R 4 is H, substituted or unsubstituted alkyl, carboxyl; and pharmaceutically acceptable salts thereof.
- R 2 is independently chosen from H, ethyl, methyl.
- the compound is salicylamine (2-hydroxybenzylamine or 2-HOBA).
- the compound may be chosen from:
- the compound may also be chosen from:
- the compounds or analogs may also be chosen from:
- the compounds may also be chosen from:
- the compounds may also be chosen from
- the compounds of the present invention can be administered by any method and such methods are well known to those skilled in the art and include, but are not limited to oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, and parenteral administration, including injectable administration such as intravenous administration, intra-arterial administration, intramuscular administration and subcutaneous administration.
- the compounds can be administered therapeutically, to treat an existing disease or condition, or prophylactically for the prevention of a disease or condition.
- composition is combined with a suitable pharmaceutical carrier, such as dextrose or sucrose.
- Methods of calculating the frequency by which the composition is administered are well-known in the art and any suitable frequency of administration can be used within the context of the present invention (e.g., one 6 g dose per day or two 3 g doses per day) and over any suitable time period (e.g., a single dose can be administered over a five minute time period or over a one hour time period, or, alternatively, multiple doses can be administered over an extended time period).
- the composition of the present invention can be administered over an extended period of time, such as weeks, months or years.
- the composition can be administered in individual servings comprising one or more than one doses (individual servings) per day, to make a daily serving comprising the total amount of the composition administered in a day or 24 hour period.
- Any suitable dose of the present composition can be used within the context of the present invention. Methods of calculating proper doses are well known in the art.
- Treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
- This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
- this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- Prevent or “preventing” refers to averting, stalling, stopping or hindering something from happening, including by advance action. There is overlap in treating and preventing.
- Effective amount refers to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition.
- a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts.
- the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose.
- the dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
- a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
- “Substituted” is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds.
- Illustrative substituents include, for example, those described below.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- the heteroatoms, such as nitrogen can have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroators. This disclosure is not intended to be limited in any manner by the permissible substituents of organic compounds.
- substitution or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g. a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- Alkyl as used herein is a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the like.
- the alkyl group can be cyclic or acyclic.
- the alkyl group can be branched or unbranched.
- the alkyl group can also be substituted or unsubstituted.
- the alkyl group can be substituted with one or more groups including, but not limited to, optionally substituted alkyl, cycloalkyl, akoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein.
- a “lower alkyl” group is an alkyl group containing from one to six (e.g., from one to four) carbon atoms.
- Alkyl is generally used to refer to both unsubstituted alkyl groups and substituted alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific substituent(s) on the alkyl group.
- halogenated alkyl specifically refers to an alkyl group that is substituted with one or more halide, e.g., fluorine, chlorine, bromine, or iodine.
- alkoxyalkyl specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below.
- alkylamino specifically refers to an alkyl group that is substituted with one or more amino groups, as described below, and the like.
- alkyl is used in one instance and a specific term such as “alkylalcohol” is used in another, it is not meant to imply that the term “alkyl” does not also refer to specific terms such as “alkylalcohol” and the like.
- cycloalkyl refers to both unsubstituted and substituted cyeloalkyl moieties
- the substituted moieties can, in addition, be specifically identified herein; for example, a particular substituted cycloalkyl can be referred to as, e.g., an “alkylcycloalkyl.”
- a substituted alkoxy can be specifically referred to as, e.g., a “halogenated alkoxy”
- a particular substituted alkenyl can be, e.g., an “alkenylalcohol,” and the like.
- the practice of using a general term, such as “cycloalkyl,” and a specific term, such as “alkylcycloalkyl,” is not meant to imply that the general term does not also include the specific term.
- Cycloalkyl as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms.
- Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl cyclohexyl, norbornyl and the like.
- heterocycloalkyl is a type of cycloalkyl group as defined above, and is included within the meaning of the term “cycloalkyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
- the cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted.
- the cycloalkyl group and heterocycloalkyl group can be substituted with one or more groups including, but not limited to, optionally substituted alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol as described herein.
- Polyalkylene group as used herein is a group having two or more CH 2 groups linked to one another.
- the polyalkylene group can be represented by a formula —(CH 2 ) a —, where “a” is an integer of from 2 to 500.
- Alkoxy also includes polymers of alkoxy groups as just described; that is, an alkoxy can be a polyether such as OA 1 -OA 2 or OA 1 -(OA 2 ) a -OA 3 , where “a” is an integer of from 1 to 200 and A 1 , A 2 , and A 3 are alkyl and/or cycloalkyl groups.
- amine or “amino” as used herein are represented by a formula NA 1 A 2 A 3 , where A 1 , 2, and A 3 can be, independently, hydrogen or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
- hydroxyl as used herein is represented by a formula ⁇ OH.
- nitro as used herein is represented by a formula ⁇ NO 2 .
- DIAMOND Diet Induced Animal Model of Non-alcoholic fatty liver Disease
- DIAMOND Diet Induced Animal Model of Non-alcoholic fatty liver Disease
- is a proprietary isogenic mouse strain that sequentially develops non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, fibrosis, and hepatocellular carcinoma in response to a high-fat, high-sugar diet.
- Disease progression in the DIAMOND mice uniquely parallels human disease progression, including histopathology.
- GTT glucose tolerance test
- animals were fasted for 12 hours and then glucose (2 g/kg bw of a 100 mg/mL glucose in sterile water) was administered by oral gavage. Blood was sampled at 0, 15, 30, 45, 60, 90, and 120 minutes after glucose administration and area under the curve was calculated. Animals were sacrificed at 24 weeks of age (12 weeks of 2-HOBA or vehicle treatment). Tissues and serum were collected for analysis.
- Liver mRNA expression was assessed via RT-qPCR for the following genes: Tnfa, Nlrp1a, Il1b, Il18, Timp1, Colla1, ProCard, Nlrp3, Casp1, Prol1b, Tgfb1, Bambi, Pdk4, and Gapdh.
- FIG. 1 a - b shows Picosirius Red staining of control and 2-HOBA treated DIAMOND mouse livers. Scoring was defined on a scale of 0 to 4. All (4 out of 4) untreated mice had a fibrosis score of 1. Three of the 2-HOBA treated mice had a score of 0, while the remaining two had a score of 1.
- FIG. 2 shows the fibrosis score in control and 2-HOBA treated DIAMOND mice.
- FIG. 3 shows gene expression profiles by qRT-PCR, including measurements of key genes in hepatic inflammation and fibrosis progression. Elevated levels of tissue inhibitors of metalloproteinases (TIMP) inhibit metalloproteinases (MMP) which allows extracelluar matrix proteins, such as collagens, to accumulate in liver tissue.
- TRIP tissue inhibitors of metalloproteinases
- MMP metalloproteinases
- the observed beneficial effects of 2-HOBA on liver fibrosis is unexpected and surprising as many NASH therapeutics have failed to improve fibrosis severity. Liver fibrosis severity is the only NASH factor that independently predicts liver-related morbidity and mortality, thus therapeutics capable of preventing or attenuating fibrosis development may dramatically improve outcomes in patients with NASH.
- the mechanism by which 2-HOBA is thought to be therapeutic for NASH is through the attenuation of inflammatory changes in the liver. Fibrosis, however, is a secondary stage pathogenesis with a different pathogenic mechanism.
- 2-HOBA independently attenuates hepatic fibrosis in the DIAMOND mice without altering markers of inflammation. As such, the results described herein are unexpected and surprising.
- HSCs hepatic stellate cells
- SMA smooth muscle actin
- Human HSCs Human stellate cells will be obtained from ZenBio (Research Triangle Park, NC) and cultured in HSC complete medium (Iscove's Modified DMEM supplemented with 20% fetal bovine serum, 2 mM glutamine, 1 ⁇ non-essential amino acids, 1 mM sodium pyruvate, and 1 ⁇ antibiotic-antimycotic). All experiments will be performed on cells between passage 3 and 5.
- RNA The expression of selected transcripts related to fibrogenic activation, cytokine production, and adhesion molecules will be measured using RT 2 ProfilerTM PCR Arrays (Qiagen, Frederick, Md.) and single-gene probe-based qRT-PCR gene expression assays, as appropriate.
- Protein Immunoblot analyses will be used to measure the content and activation status of key cell signaling pathways (ERK1/2, JNK, NF ⁇ B, and p38 MAPK). Cytokines: Inflammatory cytokine concentrations will be determined in media collected after incubation with 15-E2-IsoLG and 2-HOBA.
- ROS/RNS Intracellular ROS/RNS formation will be measured using the 5-(and-6-)-carboxy-2′-7′-dichlorodihydrofluorescein diacetate (Carboxy-H 2 ) fluorescent probe (ThermoFisher Scientific). Total cell distribution will be visualized by staining nuclei with Hoechst 33342. Images will be acquired via fluorescence microscope.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This application is a continuation-in-part of U.S. application Ser. No. 16/122,416 filed Sep. 8, 2018, which claims priority to U.S. Application Ser. No. 62/554,294 filed Sep. 5, 2017 which is herein incorporated by reference in its entirety.
- The present invention relates to a composition comprising a gamma-ketoaldehyde scavenging compound, such as 2-Hydroxybenzylamine (2-HOBA), and methods of administering a gamma-ketoaldehyde scavenger to treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of the liver.
- Liver fibrosis is a histological change caused by liver inflammation and/or chronic injury. Damage to the liver causes liver stellate cells to become overactive and triggers the extra cellular matrix (ECM) synthesis to increase. Excess amounts of collagen fiber deposits occurs in the extra-cellular spaces of the liver cells which causes the liver cells to lose blood infusion and become hardened. Fibrosis is a common aspect of many liver diseases and is defined as the formation of scar tissue in the liver. Various etiologies give rise to hepatic fibrosis, including but not limited to hepatitis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), toxins, alcoholic liver disease (ALD), genetic conditions, cholestatic disorders, and autoimmune diseases. Indicators of liver fibrosis included deposition of fibrotic tissue and activation of the fibrogenesis cascade. Fibrosis may produce permanent scarring of the hepatic tissue which is known as cirrhosis.
- In the case of NASH, there are two hallmark histologic features: hepatic inflammation and fibrosis. While no FDA-approved therapeutics for NASH exist, several potential options have been investigated; the most promising of which include vitamin E, thiazolidinediones, and pentoxifylline. Each of these has shown some borderline clinical efficacy, but all are limited by their potential for side effects and/or toxicity, and importantly, none of these therapeutics have improved fibrosis, the strongest indicator of mortality in NASH.
- γ-ketoaldehydes (γ-KA, also known as isolevuglandins or isoketals) are highly reactive lipid aldehydes that rapidly react with lysine residues and phosphatidylethanolamine to form adducts. γ-KA lipid and protein adducts have been observed in several animal models of liver disease as well as in humans with NASH. Preliminary data from humans with NASH also indicate elevated γ-KA-protein adduct formation in liver, and γ-KA-protein adducts similarly induce liver injury. γ-KA-protein adducts are linked to the loss of protein function, mitochondrial dysfunction, ER stress, and pro-inflammatory cytokine expression.
- 2-hydroxy-benzylamine (2-HOBA or salicylamine), a staple of buckwheat, was found to be a potent scavenger of γ-KAs scavenging γ-KAs 980-fold faster than the rate of formation of γ-KA-protein adducts. Studies have shown that 2-HOBA is 980 times more reactive than lysine with γ-KAs. Importantly, they showed that this γ-KA scavenger does not inhibit cyclooxygenase enzymes. Studies have shown that 2-HOBA dramatically protected HepG2 cells against H2O2-induced cytotoxicity.
- It has recently been found that γKAs induced activation of human hepatic stellate cells (HSCs) to a pro-inflammatory/pro-fibrogenic phenotype. HSCs, which make up 10% of resident liver cells, are quiescent in normal, healthy liver. However, in response to liver injury, HSCs become activated and transdifferentiate into proliferative, inflammatory myofibroblasts, which are characterized by enhanced extracellular matrix production. As such, activated HSCs are well-established as the major fibrogenic cells in the liver and are strongly implicated in the development hepatic fibrosis in states of chronic liver injury. Oxidative stress, particularly the products of lipid oxidation, has direct pro-inflammatory/pro-fibrogenic effects on HSCs. Longato et al. recently identified γKA as novel HSC activators by exposing primary human HSC to synthetic 15-E2-isolevuglandin (15-E2-IsoLG). Exposure to non-cytotoxic levels of 15-E2-IsoLG promoted HSC activation, as evidenced by upregulated α-SMA expression, MAPK activation, and increased cytokine production.
- Without being bound by theory or mechanism, the present inventors have discovered that selective scavengers of γKAs attenuate, reduce, treat, slow the progression of and/or improve hepatic fibrosis. Further, the compositions of the present invention do not present the adverse effects or toxicity associated with existing therapeutics for treating liver diseases such as NASH.
- The isoketal scavangers of the present invention are compounds such as salicylamine (SA), for example, and analogs thereof.
- The present invention includes use of gamma ketoaldehyde scavengers, including 2-HOBA, to scavenge toxic oxidized lipids (ketoaldehydes) to treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of the liver hepatic fibrosis.
- Disclosed is a method for treating, preventing and/or attenuating hepatic fibrosis that comprises identifying a subject in need of treatment, prevention and/or attenuation of hepatic fibrosis, and administering to said subject an effective isoLG scavenging amount of at least on compound of the following formula:
- wherein R2 is independently chosen from H, substituted or unsubstituted alkyl; R3 is H, halogen, alkyl, alkoxy, hydroxyl, nitro; R4 is H, substituted or unsubstituted alkyl, carboxyl; and pharmaceutically acceptable salts thereof.
- In one embodiment, R2 is independently chosen from H, ethyl, methyl. In another embodiment, the compound is 2-hydroyxbenzylamine, methyl-2-hydroyxbenzylamine, ethyl-2-hydroyxbenzylamine. In another embodiment, the compound is:
- or a pharmaceutically acceptable salt thereof.
- In another embodiment, the compound is:
- Or a pharmaceutically acceptable salt thereof.
- In one embodiment, the disclosed treating step inhibits the progression of hepatic fibrosis.
- In one embodiment, the disclosed treating step attenuates the severity of hepatic fibrosis. Also, in one embodiment, the disclosed treating step mitigates the damaging effects of hepatic fibrosis.
- In another embodiment, the compound or pharmaceutically acceptable salt thereof is administered in a composition that comprises said compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- One object of the present invention is to provide compositions used treat, prevent, attenuate, reduce, slow the progression of, and/or improve hepatic fibrosis.
- Another object of the present invention is to provide a therapeutic or effect amount of a preparation of the compound of the present invention to treat, prevent, attenuate, reduce, slow the progression of, or improve the symptoms of hepatic fibrosis and/or reduces the severity of hepatic fibrosis symptoms.
- A further object of the present invention includes providing a novel nutritional therapy that will treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of liver fibrosis. The nutritional therapy can be used to improve overall liver health and support healthy liver function.
- An additional object of the present invention includes providing compositions and methods of use of 2-HOBA, alternatively named salicylamine. SAM, 2-hydroxylbenzylamine, and pentylpyridoxamine (PPM).
-
FIGS. 1a to 1b are images of slides depicting Picosirius Red staining of fibrosis in control and 2-HOBA treated mice. -
FIG. 2 is a graph depicting the fibrosis score in control and 2-HOBA treated mice. -
FIG. 3 depicts gene expression profiles by qRT-PCR. - All publications cited or mentioned herein are incorporated by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
- The compositions described herein are used treat, prevent, attenuate, reduce, slow the progression of, and/or improve hepatic fibrosis.
- A therapeutic or effect amount is a preparation of the compound of the present invention that treat, prevent, attenuate, reduce, slow the progression of, or improve the symptoms of hepatic fibrosis and/or reduces the severity of hepatic fibrosis symptoms.
- The present invention includes a novel nutritional therapy that will treat, prevent, attenuate, reduce, slow the progression of, or improve fibrosis of liver fibrosis. The nutritional therapy can be used to improve overall liver health and support healthy liver function.
- The present invention comprises a means to specifically prevent the formation of γKA-adducts in the liver using a class of bifunctional electrophile (BFE) “scavenger” molecules. A series of phenolic amines that includes pyridoxamine and its water soluble derivative 2-HOBA, a natural product of buckwheat seed comprise the preferred embodiment. 2-HOBA in particular reacts 980-fold faster with IsoLGs than with lysine, preventing protein and lipid adduction in vitro and in vivo.
- The present invention includes compositions and methods of use of 2-HOBA, alternatively named salicylamine, SAM, 2-hydroxylbenzylamine, and pentylpyridoxamne (PPM).
- Examples of compounds of the present invention include, but are not limited (o, compounds selected from the formula or analogs thereof, and pharmaceutical salts thereof:
- wherein:
- R is N or C;
- R2 is independently H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R2, R3 and R4, and may cyclize with to one or more R2, R3, or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R3 is H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2 or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R4 is H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2, R3, or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R5 is a bond, H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2, R3, or R4 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- and stereoisomers and analogs thereof.
- Another embodiment of the present invention includes compounds of the following formula, and their use in methods for treating, preventing, or ameliorating liver fibrosis to a subject with or at risk of liver fibrosis:
- wherein:
- R is N or C;
- R2 is independently H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R2, R3 and R4, and may cyclize with to one or more R2, R3, or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R3 is H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2 or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R4 is H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2, R3, or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R5 is a bond, H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2, R3, or R4 to form an optionally substituted C3-8 membered ring containing C, O, S or N; and stereoisomers and analogs thereof.
- In certain embodiments, the compound may be selected from the compounds disclosed herein. In a preferred embodiment, the compound may be salicylamine. Other compounds that may be used include methyl-2-HOBA or ethyl-2-HOBA. The present invention includes administering to a patient in need thereof an effective amount of at least one isoLG scavenger compound of the present invention, or a pharmaceutically acceptable salt thereof.
- Another embodiment of the present invention is a method for treating, preventing, or ameliorating liver fibrosis to a subject with or at risk of liver fibrosis, thereby inhibiting or treating the liver fibrosis, comprising the step of co-administering to the subject at least one compound in a dosage and amount effective to treat the dysfunction in the mammal, the compound having a structure represented by a compound of the following formula:
- wherein:
- R is N or C;
- R2 is independently H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R2, R3 and R4, and may cyclize with to one or more R2, R3, or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R3 is H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2 or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R4 is H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2, R3, or R5 to form an optionally substituted C3-8 membered ring containing C, O, S or N;
- R5 is a bond, H, hydroxy, halogen, nitro, CF3, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, C3-8 membered ring containing C, O, S or N, optionally substituted with one or more R4, R2 and R3 may cyclize with to one or more R2, R3, or R4 to form an optionally substituted C3-8 membered ring containing C, O, S or N; and stereoisomers and analogs thereof; with a drug having a known side effect of treating, preventing, or ameliorating liver fibrosis.
- Examples of compounds that may be used with the methods disclosed herein include, but are not limited to, compounds selected from the formula:
- wherein:
- R2 is independently H, substituted or unsubstituted alkyl;
R3 is H, halogen, alkoxy, hydroxyl, nitro;
R4 is H, substituted or unsubstituted alkyl, carboxyl; and pharmaceutically acceptable salts thereof. - Further example include compounds of the following formula:
- wherein: R2 is independently chosen from H, substituted or unsubstituted alkyl; R3 is H, halogen, alkyl, alkoxy, hydroxyl, nitro; R4 is H, substituted or unsubstituted alkyl, carboxyl; and pharmaceutically acceptable salts thereof. In other embodiments, R2 is independently chosen from H, ethyl, methyl.
- In a preferred embodiment, the compound is salicylamine (2-hydroxybenzylamine or 2-HOBA).
- The compound may be chosen from:
- or a pharmaceutically acceptable salt thereof.
- The compound may also be chosen from:
- or a pharmaceutically acceptable salt thereof.
- The compounds or analogs may also be chosen from:
- or a pharmaceutically acceptable salt thereof.
- The compounds may also be chosen from:
- or a pharmaceutically acceptable salt thereof.
- The compounds may also be chosen from
- or a pharmaceutically acceptable salt thereof.
- The compounds of the present invention can be administered by any method and such methods are well known to those skilled in the art and include, but are not limited to oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, and parenteral administration, including injectable administration such as intravenous administration, intra-arterial administration, intramuscular administration and subcutaneous administration. The compounds can be administered therapeutically, to treat an existing disease or condition, or prophylactically for the prevention of a disease or condition.
- Although any suitable pharmaceutical medium comprising the composition can be utilized within the context of the present invention, preferably, the composition is combined with a suitable pharmaceutical carrier, such as dextrose or sucrose.
- Methods of calculating the frequency by which the composition is administered are well-known in the art and any suitable frequency of administration can be used within the context of the present invention (e.g., one 6 g dose per day or two 3 g doses per day) and over any suitable time period (e.g., a single dose can be administered over a five minute time period or over a one hour time period, or, alternatively, multiple doses can be administered over an extended time period). The composition of the present invention can be administered over an extended period of time, such as weeks, months or years. The composition can be administered in individual servings comprising one or more than one doses (individual servings) per day, to make a daily serving comprising the total amount of the composition administered in a day or 24 hour period.
- Any suitable dose of the present composition can be used within the context of the present invention. Methods of calculating proper doses are well known in the art.
- “Treatment” or “treating” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- “Prevent” or “preventing” refers to averting, stalling, stopping or hindering something from happening, including by advance action. There is overlap in treating and preventing.
- “Effective amount” refers to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
- “Substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described below. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, the heteroatoms, such as nitrogen, can have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroators. This disclosure is not intended to be limited in any manner by the permissible substituents of organic compounds. Also, the terms “substitution” or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g. a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- “Alkyl” as used herein is a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group can be cyclic or acyclic. The alkyl group can be branched or unbranched. The alkyl group can also be substituted or unsubstituted. For example, the alkyl group can be substituted with one or more groups including, but not limited to, optionally substituted alkyl, cycloalkyl, akoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein. A “lower alkyl” group is an alkyl group containing from one to six (e.g., from one to four) carbon atoms.
- “Akyl” is generally used to refer to both unsubstituted alkyl groups and substituted alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific substituent(s) on the alkyl group. For example, the term “halogenated alkyl” specifically refers to an alkyl group that is substituted with one or more halide, e.g., fluorine, chlorine, bromine, or iodine. The term “alkoxyalkyl” specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below. The term “alkylamino” specifically refers to an alkyl group that is substituted with one or more amino groups, as described below, and the like. When “alkyl” is used in one instance and a specific term such as “alkylalcohol” is used in another, it is not meant to imply that the term “alkyl” does not also refer to specific terms such as “alkylalcohol” and the like.
- This practice is also used for other groups described herein. That is, while a term such as “cycloalkyl” refers to both unsubstituted and substituted cyeloalkyl moieties, the substituted moieties can, in addition, be specifically identified herein; for example, a particular substituted cycloalkyl can be referred to as, e.g., an “alkylcycloalkyl.” Similarly, a substituted alkoxy can be specifically referred to as, e.g., a “halogenated alkoxy,” a particular substituted alkenyl can be, e.g., an “alkenylalcohol,” and the like. Again, the practice of using a general term, such as “cycloalkyl,” and a specific term, such as “alkylcycloalkyl,” is not meant to imply that the general term does not also include the specific term.
- “Cycloalkyl” as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl cyclohexyl, norbornyl and the like. The term “heterocycloalkyl” is a type of cycloalkyl group as defined above, and is included within the meaning of the term “cycloalkyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted. The cycloalkyl group and heterocycloalkyl group can be substituted with one or more groups including, but not limited to, optionally substituted alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol as described herein.
- “Polyalkylene group” as used herein is a group having two or more CH2 groups linked to one another. The polyalkylene group can be represented by a formula —(CH2)a—, where “a” is an integer of from 2 to 500.
- The terms “alkoxy” and “alkoxyl” as used herein to refer to an alkyl or cycloalkyl group bonded through an ether linkage; that is, an “alkoxy” group can be defined as —OA1 where A1 is alkyl or cycloalkyl as defined above. “Alkoxy” also includes polymers of alkoxy groups as just described; that is, an alkoxy can be a polyether such as OA1-OA2 or OA1-(OA2)a-OA3, where “a” is an integer of from 1 to 200 and A1, A2, and A3 are alkyl and/or cycloalkyl groups.
- The terms “amine” or “amino” as used herein are represented by a formula NA1A2A3, where A1, 2, and A3 can be, independently, hydrogen or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
- The term “hydroxyl” as used herein is represented by a formula ˜OH.
- The term “nitro” as used herein is represented by a formula ˜NO2.
- DIAMOND (Diet Induced Animal Model of Non-alcoholic fatty liver Disease) is a proprietary isogenic mouse strain that sequentially develops non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, fibrosis, and hepatocellular carcinoma in response to a high-fat, high-sugar diet. Disease progression in the DIAMOND mice uniquely parallels human disease progression, including histopathology.
- Twelve 8-wk old male DIAMOND mice were placed on ad libitum high fat diet (Harlan-ENVIGO TD.88317) and water containing glucose (18.9% w/v) and fructose (23.1% w/v); all mice remained on this diet throughout the study protocol. At 12 weeks of age, mice were divided into two groups: 1) 2-HOBA (n=6), and 2) vehicle controls (n=6). Animals in the 2-HOBA group received 2-HOBA in drinking water (1 g/L water with glucose and fructose). The vehicle control group received water without 2-HOBA (with glucose and fructose). Body weight and food intake were measured weekly. At ˜23 weeks of age, all animals underwent a glucose tolerance test (GTT) and MRI imaging to assess hepatic fat. For the GTT, animals were fasted for 12 hours and then glucose (2 g/kg bw of a 100 mg/mL glucose in sterile water) was administered by oral gavage. Blood was sampled at 0, 15, 30, 45, 60, 90, and 120 minutes after glucose administration and area under the curve was calculated. Animals were sacrificed at 24 weeks of age (12 weeks of 2-HOBA or vehicle treatment). Tissues and serum were collected for analysis.
- Liver sections were stained with hematoxylin and eosin (for scoring of steatosis, hepatocyte ballooning, and inflammation) and Sirius red (for assessment of fibrosis). Scoring was performed in a blinded manner for steatosis, ballooning, inflammation, and necrosis using the following criteria1, Steatosis (0-4): 0=<5%; 1=5-25%; 2=25-50%; 3=50-75%; 4=75-100%. Ballooning (0-3): 0=absent; 1=mild (focal involving fewer than three hepatocytes); 2=moderate (focal involving more than three hepatocytes or multifocal); 3=prominent (multifocal with more than two foci of three or more hepatocytes). Inflammation (0-4): 0=absent; 1=minimal (zero to one focus per 20× field); 2=mild (two foci); 3=moderate (three foci); 4=severe (four or more foci). Serum levels of glucose, alanine transaminase, and aspartate transaminase were measured. Liver mRNA expression was assessed via RT-qPCR for the following genes: Tnfa, Nlrp1a, Il1b, Il18, Timp1, Colla1, ProCard, Nlrp3, Casp1, Prol1b, Tgfb1, Bambi, Pdk4, and Gapdh. Two-tailed independent samples t-tests were used to compare endpoints between 2-HOBA and vehicle treated groups. Significance was set at α=0.05.
-
FIG. 1a-b shows Picosirius Red staining of control and 2-HOBA treated DIAMOND mouse livers. Scoring was defined on a scale of 0 to 4. All (4 out of 4) untreated mice had a fibrosis score of 1. Three of the 2-HOBA treated mice had a score of 0, while the remaining two had a score of 1. -
FIG. 2 shows the fibrosis score in control and 2-HOBA treated DIAMOND mice. - Despite similar degrees of hepatic steatosis and hepatocellular ballooning, the incidence of fibrosis was significantly lower in 2-HOBA compared to vehicle treated DIAMOND mice (p=0.03).
-
FIG. 3 shows gene expression profiles by qRT-PCR, including measurements of key genes in hepatic inflammation and fibrosis progression. Elevated levels of tissue inhibitors of metalloproteinases (TIMP) inhibit metalloproteinases (MMP) which allows extracelluar matrix proteins, such as collagens, to accumulate in liver tissue. 2-HOBA reduced liver Timp1 mRNA expression in DIAMOND mice, explaining the observed beneficial effect of 2-HOBA on fibrosis development. Further, Colla1 mRNA expression levels tended to be lower. This difference was not statistically significant (p=0.08). - The observed beneficial effects of 2-HOBA on liver fibrosis is unexpected and surprising as many NASH therapeutics have failed to improve fibrosis severity. Liver fibrosis severity is the only NASH factor that independently predicts liver-related morbidity and mortality, thus therapeutics capable of preventing or attenuating fibrosis development may dramatically improve outcomes in patients with NASH. The mechanism by which 2-HOBA is thought to be therapeutic for NASH is through the attenuation of inflammatory changes in the liver. Fibrosis, however, is a secondary stage pathogenesis with a different pathogenic mechanism. 2-HOBA independently attenuates hepatic fibrosis in the DIAMOND mice without altering markers of inflammation. As such, the results described herein are unexpected and surprising.
- γ-KAs induce activation of hepatic stellate cells (HSCs), which are the primary drivers of hepatic fibrosis. Preventing the activation of HSCs to a pro-inflammatory/pro-fibrogenic phenotype could inhibit the development of fibrosis in the liver. As transformation of HSCs into myofibroblast-like cells is considered essential for hepatic fibrosis, HSC activation will be measured using desmin, a marker of HSCs, and α-smooth muscle actin (SMA), a marker of activated HSCs, by immunohistochemistry on fixed liver sections.
- Experimental Design: All experiments will be performed on 24-h-serum-starved HSCs. To prevent γKA adduction to culture media components, experimental treatments will be initiated in amino-acid and lipid-free Hank's Buffered Salt Solution for the first 15 min of exposure. This exposure duration has previously been determined to be well-tolerated by human HSCs. Human HSCs will be pre-incubated with multiple doses (1-500 M) of 2-HOBA or vehicle before being exposed to 0.5 μM 15-E2-IsoLG. Time course experiments with 2-HOBA and 15-E2-levuglandin will be performed to determine the optimal durations for pre-treatment and 15-E2-soLG exposure. Following 15-E2-IsoLG exposure, media will be collected and cells will be washed and scraped for mRNA and protein analyses. Separate replicate plates will be prepared for ROS measurements.
- Human HSCs: Human stellate cells will be obtained from ZenBio (Research Triangle Park, NC) and cultured in HSC complete medium (Iscove's Modified DMEM supplemented with 20% fetal bovine serum, 2 mM glutamine, 1× non-essential amino acids, 1 mM sodium pyruvate, and 1× antibiotic-antimycotic). All experiments will be performed on cells between passage 3 and 5.
- 15-E2-isolevuglandin: Synthetic 15-E2-IsoLG in DMSO will be synthesized as previously described by our consultant.
- Endpoints: RNA: The expression of selected transcripts related to fibrogenic activation, cytokine production, and adhesion molecules will be measured using RT2 Profiler™ PCR Arrays (Qiagen, Frederick, Md.) and single-gene probe-based qRT-PCR gene expression assays, as appropriate. Protein: Immunoblot analyses will be used to measure the content and activation status of key cell signaling pathways (ERK1/2, JNK, NFκB, and p38 MAPK). Cytokines: Inflammatory cytokine concentrations will be determined in media collected after incubation with 15-E2-IsoLG and 2-HOBA. ROS/RNS: Intracellular ROS/RNS formation will be measured using the 5-(and-6-)-carboxy-2′-7′-dichlorodihydrofluorescein diacetate (Carboxy-H2) fluorescent probe (ThermoFisher Scientific). Total cell distribution will be visualized by staining nuclei with Hoechst 33342. Images will be acquired via fluorescence microscope.
- Statistics: All experiments will be performed in triplicate. Data will be analyzed by one-way (dose) or two-way (dose×time) ANOVA (as appropriate for the design), with Bonferroni's multiple comparisons tests.
-
- 1 Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846, doi:10.1002/hep.24001 (2010).
- 2 Brame, C. J., Salomon, R. G., Morrow, J. D. & Roberts, L. J. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J. Biol. Chem 274, 13139-13146 (1999).
- 3 Li, W. et al. Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts. Free Radic. Biol. Med 47, 1539-1552 (2009).
- 4 Roychowdhury, S. et al. Formation of gamma-ketoaldehyde-protein adducts during ethanol-induced liver injury in mice. Free Radic. Biol. Med 47, 1526-1538 (2009).
- 5 Li, X. et al. Endoplasmic reticulum stress is the crossroads of autophagy, inflammation, and apoptosis signaling pathways and participates in liver fibrosis. Inflamm Res 64, 1-7, doi:10.1007/s00011-014-0772-y (2015).
- 6 Konishi, M. et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol. Hepatol 21, 1821-1825 (2006).
- 7 Davies, S. S. et al. Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB J 16, 715-717(2002).
- 8 Guo, L. et al. Phosphatidylethanolamines modified by gamma-ketoaldehyde (gammaKA) induce endoplasmic reticulum stress and endothelial activation. J. Biol. Chem 286, 18170-18180 (2011).
- 9 Stavrovskaya, I. G. et al. Reactive gamma-ketoaldehydes formed via the isoprostane pathway disrupt mitochondrial respiration and calcium homeostasis. Free Radic. Biol. Med 49, 567-579 (2010).
- Mont, S. et al. Accumulation of isolevuglandin-modified protein in normal and fibrotic lung. Sci. Rep 6, 24919 (2016).
- 11 Longato, L. et al. Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro. Free Radic Biol Med 102, 162-173, doi:10.1016/j.freeradbiomed.2016.11.036 (2017).
- 12 Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, doi:10.1002/hep.29466 (2017).
- 13 Wadden, T. A. et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 365, 1969-1979, doi:10.1056/NEJMoa1109220 (2011).
- 14 Browning, J. D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395, doi:10.1002/hep.20466 (2004).
- 15 Williams, C. D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124-131, doi:10.1053/j.gastro.2010.09.038 (2011).
- 16 Kim, C. H. & Younossi, Z. M. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve. Clin. J. Med 75, 721-728 (2008).
- 17 Pagano, G. et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35, 367-372 (2002).
- 18 Karlas, T., Wiegand, J. & Berg, T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrino/Metab 27, 195-208, doi:10.1016/j.beem.2013.02.002 (2013).
- 19 Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C. & Marchesini, G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53, 372-384, doi:10.1016/j.jhep.2010.04.008 (2010).
- Charlton, M. R. et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141, 1249-1253 (2011).
- 21 Fujii, M. et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med. Mol. Morphol 46, 141-152 (2013).
- 22 Asgharpour, A. et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 65, 579-588, doi:10.1016/j.jhep.2016.05.005 (2016).
- 23 lyer, R. S., Ghosh, S. & Salomon, R. G. Levuglandin E2 crosslinks proteins. Prostaglandins 37, 471-480(1989).
- 24 Murthi, K. K., Friedman, L. R., Oleinick, N. L. & Salomon, R. G. Formation of DNA-protein crosslinks in mammalian cells by levuglandin E2. Biochemistry 32, 4090-4097 (1993).
- Morrow, J. D. et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U. S. A 87, 9383-9387 (1990).
- 26 Salomon, R. G. & Miller, D. B. Levuglandins: isolation, characterization, and total synthesis of new secoprostanoid products from prostaglandin endoperoxides. Adv. Prostaglandin Thromboxane Leukot. Res 15, 323-326 (1985).
- 27 Bernoud-Hubac, N. et al. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. Biochim. Biophys. Acta 1791, 307-313 (2009).
- 28 Sullivan, C. B., Matafonova, E., Roberts, L. J., Amarnath, V. & Davies, S. S. Isoketals form cytotoxic phosphatidylethanolamine adducts in cells. J. Lipid Res 51, 999-1009 (2010).
- 29 Haukeland, J. W. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol 44, 1167-1174 (2006).
- 30 Kojima, H. et al. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin. Exp. Res 31, S61-S66 (2007).
- 31 Elizondo, A. et al. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol. Res 41, 59-68 (2008).
- 32 Wake, K. “Sternzellen” in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat 132, 429-462, doi:10.1002/aja.1001320404 (1971).
- 33 Puche, J. E., Saiman, Y. & Friedman, S. L. Hepatic stellate cells and liver fibrosis. Compr Physiol 3, 1473-1492, doi:10.1002/cphy.c120035 (2013).
- 34 Marra, F. et al. Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med 47, 66-75 (1999).
- 35 Parola, M. et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1(1) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 194, 1044-1050, doi:10.1006/bbrc.1993.1927 (1993).
- 36 Parola, M. et al. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest 102, 1942-1950, doi:10.1172/JC11413 (1998).
- 37 Zamara, E. et al. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 40, 60-68 (2004).
- 38 Amarnath, V., Amarnath, K., Amarnath, K., Davies, S. & Roberts, L. J. Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem Res. Toxicol 17, 410-415 (2004).
- 39 Davies, S. S. et al. Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity. Biochemistry 45, 15756-15767 (2006).
- 40 Hagstrom, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol, doi:10.1016/j.jhep.2017.07.027 (2017).
- 41 Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965, doi:10.1016/S0140-6736(14)61933-4 (2015).
- 42 Zagol-Ikapitte, I. A. et al. Determination of the Pharmacokinetics and Oral Bioavailability of Salicylamine, a Potent gamma-Ketoaldehyde Scavenger, by LC/MS/MS.
Pharmaceutics 2, 18-29 (2010). - 43 Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
- 44 Amarnath, V., Amarnath, K., Masterson, T., Davies, S. & Roberts, L. J. A Simplified Synthesis of the Diastereomers of Levuglandin E2. Synthetic Communications 35, 397-408, doi:10.1081/SCC-200048945 (2005).
Claims (12)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/064,154 US20210023032A1 (en) | 2017-09-05 | 2020-10-06 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
US18/213,416 US20230330049A1 (en) | 2017-09-05 | 2023-06-23 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762554294P | 2017-09-05 | 2017-09-05 | |
US16/122,416 US20190099387A1 (en) | 2017-09-05 | 2018-09-05 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
US17/064,154 US20210023032A1 (en) | 2017-09-05 | 2020-10-06 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/122,416 Continuation-In-Part US20190099387A1 (en) | 2017-09-05 | 2018-09-05 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/213,416 Continuation US20230330049A1 (en) | 2017-09-05 | 2023-06-23 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210023032A1 true US20210023032A1 (en) | 2021-01-28 |
Family
ID=74189810
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/064,154 Abandoned US20210023032A1 (en) | 2017-09-05 | 2020-10-06 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
US18/213,416 Pending US20230330049A1 (en) | 2017-09-05 | 2023-06-23 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/213,416 Pending US20230330049A1 (en) | 2017-09-05 | 2023-06-23 | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
Country Status (1)
Country | Link |
---|---|
US (2) | US20210023032A1 (en) |
-
2020
- 2020-10-06 US US17/064,154 patent/US20210023032A1/en not_active Abandoned
-
2023
- 2023-06-23 US US18/213,416 patent/US20230330049A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230330049A1 (en) | 2023-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8088951B2 (en) | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss | |
RU2617502C2 (en) | S1p receptor modulators for multiple sclerosis treatment | |
CA2949480A1 (en) | Compositions of pentosan polysulfate salts for oral administration and methods of use | |
JP2019511478A (en) | Methods for using FXR agonists | |
CN111182904A (en) | Combination therapy comprising ACC inhibitors | |
JP2003535034A (en) | Dipeptidyl peptidase IV inhibitors and methods for producing and using dipeptidyl peptidase IV inhibitors | |
TW201811372A (en) | Methods for using FXR agonists | |
TW201815420A (en) | Methods for using FXR agonists | |
KR20230023642A (en) | Combination treatment of liver failure | |
KR102205368B1 (en) | New therapies for FXR agonists | |
US20190099387A1 (en) | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver | |
US20210023032A1 (en) | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver | |
JP2009196959A (en) | Pharmaceutical composition for treatment of cancer | |
US8642566B2 (en) | Therapeutic approaches for treating neuroinflammatory conditions | |
US11628163B2 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
EP3965769B1 (en) | Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease | |
WO2020087937A1 (en) | Composition for treating liver cancer accompanied by fibrosis | |
JP2022515615A (en) | Use of PAR-1 antagonists for the treatment of chronic inflammatory bowel disease | |
WO2007010946A1 (en) | Synovial cell proliferation inhibitor | |
US20240216384A1 (en) | Composition for preventing or treating metabolic diseases, containing tricyclo derivative compound | |
EP4331587A1 (en) | Composition for preventing or treating metabolic diseases, containing tricyclo derivative compound | |
US20240148764A1 (en) | Inhibitors of sglt-1 and uses thereof | |
WO2022019235A1 (en) | Utilization of vitamin b12 in inhibiting renal disorder | |
EP4166137A1 (en) | Therapeutic agent for fatty liver disease | |
Yu et al. | The variations of Endophilin A2-FoxO3a-autophagy signal in AngⅡ-induced dopaminergic neuron injury mouse model and By Biochanin A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |